Therapy Resistance and Metabolic reprogramming in ER+ breast cancer: what a combo – Andrea Morandi

📣 It’s OUT!

Therapy Resistance and Metabolic reprogramming in ER+ breast cancer: what a combo! An exciting journey in collaboration with Elisabetta Marangoni’s team at the Institut Curie joying our interest in therapy resistance and metabolic deregulation.

🔬 👨‍🔬 A phenomenal effort of Elisabetta’s team with 14 PDX generated resembling the landscape of ER+ BC: from endocrine to CDK4/6i resistant models, to bone met metastasis matched to primary tumours. Patients’ derived material and functional data on isogenic cell models implemented the PDX data

1️⃣ High expression of OXPHOS-related genes is associated with worse survival in breast cancer
2️⃣ OXPHOS is a metabolic vulnerability in preclinical models of ER+ metastatic BC with endocrine and CDK4/6i resistance
3️⃣ PIK3CA/AKT1 genes and MYC status predicts OXPHOS inhibitor response.

For article: Click here

Source: Andrea Morandi/Linkedin